If a patient is already a low cholesterol producer at baseline and we suppress that further, we risk under-supplying the brain, which depends heavily on cholesterol to build myelin, the wiring for neurons
Thus, while the widespread adoption of GLP-1 medications creates investment opportunities (in companies that manufacture healthier food choices, for example), it also poses risks for many consumer sectors
Current data shows that approximately 75% of private payers now include GLP-1 medications on their formularies for specific health conditions
Development of Exenatide: One of the first GLP-1 receptor agonists to be developed and approved for use was Exenatide, sold under the brand name Byetta
No, semaglutide does not interfere with celiac disease management or change your gluten-free diet requirements
The medications are different drugs with different dosing ranges